Attached files

file filename
EX-10.67 - EXHIBIT 10.67 - Fortress Biotech, Inc.v404830_ex10-67.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

  FORM 8-K  

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 12, 2015

 

 

 CORONADO BIOSCIENCES, INC.

 
 

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware 001-35366 20-5157386

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

             24 New England Executive Park, Burlington, MA                            01803
                 (Address of Principal Executive Offices)                                       (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 652-4500

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

qWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

qSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

qPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

qPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 1.01.Entry into a Material Definitive Agreement.

 

On March 12, 2015, the Compensation Committee of the Board of Directors (the “Board”) of Coronado Biosciences, Inc. (the “Company”) approved a deferred compensation plan (the “Plan”) for non-employee directors (“Participants”). The Plan, to be administered by the Compensation Committee, is intended to be a non-qualified benefit plan for purposes of the Employee Retirement Income Security Act of 1974, as amended.

 

Pursuant to the Plan, a Participant can defer all or a portion of Participant’s unearned annual fees, meeting fees, and committee fees, including restricted stock and restricted stock units. Deferred cash compensation will be converted into a number of stock units, determined based upon the closing price of the Company’s common stock on the date such fees would otherwise have been payable and placed into the Participant’s deferred compensation account (“Account”). Deferred restricted stock unit grants will be converted on a share-for-share basis on the date such restricted stock units would otherwise have been payable and placed into the Participant’s Account.

 

On the tenth business day of January of the year following the Participant’s termination of service on the Board due to resignation, removal, failure to be re-elected, or retirement, the amount of deferred compensation in the Participant’s Account will be distributed to the Participant in a lump sum payment of a number of shares of the Company’s common stock under the Company’s 2013 Stock Incentive Plan, as may be amended, equal to the number of whole stock units in the Account and cash in lieu of any fractional shares. Distributions from the Account may be accelerated in the event of the Participant’s death or upon a corporate transaction (as defined in the Plan).

 

The above description of the Plan is qualified in its entirety by reference to the full and complete terms of the Plan, which is filed as Exhibit 10.67 to this Current Report on Form 8-K.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No.   Description
     
10.67   Coronado Biosciences, Inc. Deferred Compensation Plan for Directors, dated March 12, 2015.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CORONADO BIOSCIENCES, INC.
     
Date: March 18, 2015 /s/ Lucy Lu
  Name:    Lucy Lu
  Title: Executive Vice President and Chief Financial Officer